PARP Inhibitor Combinations in Prostate Cancer: Immune Checkpoint Inhibitors and Other Agents

This downloadable slide set from a live Webinar explores the rationale for combining PARP inhibitors with different types of agents for advanced prostate cancer, including immunotherapy, targeted agents, and radionuclides, incorporating the latest evidence from ASCO GU 2021.
Charles J. Ryan, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.52 MB
Released: February 19, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AstraZeneca
Merck Sharp & Dohme Corp.
Pfizer

Related Content

Comentario de un experto sobre las terapias de combinación que utilizan inhibidores de PARP más otros agentes en el cáncer de próstata avanzado de Clinical Care Options (CCO).

Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD Released: February 25, 2021

Commentaire des experts sur les associations thérapeutiques utilisant les inhibiteurs PARP et d'autres agents dans le traitement du cancer avancé de la prostate, extrait de Clinical Care Options (CCO)

Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD Released: February 25, 2021

Downloadable slideset with key highlight data from the virtual 2021 ASCO GU Cancers Symposium provided by Clinical Care Options (CCO)

Robert Motzer, MD Daniel P. Petrylak, MD Released: February 25, 2021

Downloadable slideset from Clinical Care Options (CCO) exploring early data and on ongoing clinical trials combining AR-directed therapy with PARP inhibition.

person default Neal D. Shore, MD, FACS Released: February 19, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue